HCW Biologics raises ~$4.0M in private placement at $1.405/unit

HCW Biologics Inc.

Sold 2,846,975 units at $1.405 each, each comprising 1 share (or pre-funded warrant at $1.2799) and 1 warrant exercisable at $1.28.
Gross proceeds of ~$4.0M before fees; net proceeds for HCW9302 clinical trials and IND-enabling studies for HCW11-018b and HCW11-040.
E.F. Hutton acted as sole placement agent; closing expected May 21, 2026.
Registration rights agreement filed within 60 days; warrants expire 5.5 years from issuance.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

HCW Biologics Inc. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate gross proceeds of approximately $4.0 million (effective 2026-05-21).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: aggregate gross proceeds of approximately $4.0 million
Effective: 2026-05-21

Exact text from the filing

On May 21, 2026, HCW Biologics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 2,846,975 units

View on SEC.gov

Browse all material agreements →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-024850

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.